Thursday, 15 October 2026European Markets

AURES TECHNOLOGIES Stock Went Up By Over 22% In The Last 10 Sessions

Loading stream...

(vianews) - shares of aures technologies (cac 40: aurs.pa) rose by a staggering 22.76% in 10 sessions from €5.8 to €7.12 at 05:37 est on wednesday, after four consecutive sessions in a row of losses. cac 40 is sliding 0.16% to €7,406.01, following the last session's downward trend.

about aures technologies

aures technologies s.a. engages in manufacture of hardware and digital application solutions for point of sale and retail industry. the company provides all-in-one touch screen terminals, pos systems, and retail solutions; kiosk products; pos and mobile tablets; touchscreen panels; pos thermal receipt printers; complementary screens, displays, and monitors; and a range of accessories, such as barcode scanners, specific readers for magnetic cards, biometric readers, and rfid readers. it also offers consulting, staging, installation, decommissioning, asset tracking, real time pos monitoring, and onsite support services. the company offers its products for food and non-food stores, shops, retail outlets, superstores and supermarkets, catering and hospitality businesses, snacking and takeaway outlets, leisure and sport venues, etc. it markets its products through a network of distributors, resellers, agents, and partners in france, the united kingdom, germany, australia, the united states, and internationally. the company was incorporated in 1989 and is headquartered in lisses, france.

earnings per share

as for profitability, aures technologies has a trailing twelve months eps of €0.37.

pe ratio

aures technologies has a trailing twelve months price to earnings ratio of 19.45. meaning, the purchaser of the share is investing €19.45 for every euro of annual earnings.

more news about aures technologies (aurs.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com